Table 3.
Estimated odds ratios for multivariable logistic regression models for the outcome of receiving a statin prescription.
| Model 1 | Model 2a | |||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Aminotransferase Variable | ||||
| Elevated AST or ALT | 0.88 | 0.62 - 1.25 | 1.17 | 0.78 - 1.76 |
| Comorbidities | ||||
| NAFLD, diagnosed | 1.18 | 0.79 - 1.75 | 1.29 | 0.84 - 1.98 |
| Cardiovascular disease | 1.52 | 1.00 - 2.32 | 1.72 | 1.09 - 2.71 |
| Diabetes | 2.29 | 1.61 - 3.26 | 2.61 | 1.73 - 3.92 |
| Hypertension | 4.20 | 2.71 - 6.53 | 2.76 | 1.70 - 4.48 |
| Demographics | ||||
| Age, years | 1.06 | 1.05 - 1.08 | ||
| Male (Female ref.) | 0.77 | 0.52 - 1.13 | ||
| Black (non-Black ref.) | 1.04 | 0.68 - 1.58 | ||
| Clinical Variables | ||||
| BMI ≥ 30 kg/m2 | 1.49 | 1.01 - 2.22 | ||
| High-risk Advanced Fibrosis Assessments | ||||
| FIB-4 (≥ 2.67) | 0.87 | 0.45 - 1.68 | ||
| NFS (≥ 0.676) | 0.59 | 0.34 - 1.04 | ||
a
Bilirubin, alkaline phosphatase, and plaletet count were originally included in the model, but were not significant and removal did not impact overall model fit (c=0.794). Sensitivity analyses with: elevated AST and ALT, elevated AST, elevated ALT, AST (continuous), and ALT (continuous) were performed with no significant change in results.
OR=odds ratio. CI=confidence interval. AST=aspartate aminotransferase. ALT=alanine aminotransferase. FIB-4=Fibrosis-4 Index. NFS=NAFLD Fibrosis Score.